Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ajanta Pharma Limited (AJANTPHARM.NS)
INR3,454.20
+45.40 (+1.33%)
IN NSE Healthcare Drug Manufacturers - Specialty & Generic
Address
Ajanta House 400067
Mumbai, IN
Mumbai, IN
CEO
Yogesh Mannalal Agrawal
Website
ajantapharma.com
IPO
2002-07-01
ISIN INE031B01049
Also trades on
Bombay Stock Exchange · AJANTPHARM.BO (INR)
National Stock Exchange of India · AJANTPHARM.NS (INR)
Description
Established in 1973 and headquartered in Mumbai, India, Ajanta Pharma Limited operates as a specialized pharmaceutical enterprise. This company, along with its subsidiaries, is dedicated to the development, manufacturing, and commercialization of finished dosage forms. Its extensive product range caters to numerous therapeutic categories, such as anti-infectives (antibiotic, anti-malarial), chronic disease management (anti-diabetic, cardiology), women's health (gynecology), pediatrics, respiratory ailments, general health, dermatology, ophthalmology, and pain management. Notable products include multivitamins, antibiotics, eye drops, and cough syrups. Ajanta Pharma boasts a substantial international footprint, operating across India, Africa, other parts of Asia, the United States, and additional global markets. Furthermore, it supplies its pharmaceutical offerings to various government entities, including armed forces, public hospitals, and governmental procurement departments.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
INR3,454.20
+45.40 (+1.33%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
134.9K
Beta
0.20
Float Shares
41.98M
Free Float %
33.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.82% | +0.55% | +11.08% | +7.85% | +21.38% | +12.57% | +25.57% | +146.80% | +133.18% | +205.16% | +19,803.58% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
3,454.20
DCF (Unlevered)
6,917.66
+100.3%
DCF (Levered)
10,553.07
+205.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
83% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 9 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 2 | 0 |
Quality scores
Altman Z-Score
16.29
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
9 / 10
Strong MOAT
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
★ Strong MOAT
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+18.9% ★ Q1'26: +28.1% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+15.0% Q1'26: +18.3% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+6.1% Q1'26: +7.8% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+24.3% ★ Q1'26: +23.2% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+24.6% ★ Q1'26: +24.6% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.2% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.17× ★ Q1'26: 0.20× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2012 actual |
Mar 2013 actual |
Mar 2014 actual |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 12 Rev. Ana. 11 EPS Ana. |
Mar 2027 11 Rev. Ana. 11 EPS Ana. |
Mar 2028 11 Rev. Ana. 12 EPS Ana. |
Mar 2029 5 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
6.69B
est: 6.17B (+8.4%)
|
9.22B
est: 8.96B (+2.9%)
|
11.81B
est: 11.98B (-1.4%)
|
14.48B
est: 14.19B (+2.1%)
|
17.14B
est: 17.63B (-2.8%)
|
19.16B
est: 20.54B (-6.7%)
|
20.60B
est: 21.00B (-1.9%)
|
20.16B
est: 20.37B (-1.0%)
|
25.62B
est: 25.28B (+1.3%)
|
28.45B
est: 28.59B (-0.5%)
|
32.84B
est: 32.60B (+0.7%)
|
37.08B
est: 38.18B (-2.9%)
|
41.62B
est: 43.33B (-3.9%)
|
45.88B
est: 46.13B (-0.6%)
|
53.65B
51.59B – 54.81B
+16.3% YoY
|
62.10B
59.83B – 63.71B
+15.8% YoY
|
69.89B
67.12B – 72.16B
+12.5% YoY
|
78.08B
77.88B – 78.29B
+11.7% YoY
|
| EBITDA |
1.35B
est: 1.83B (-26.4%)
|
2.24B
est: 1.56B (+44.2%)
|
3.80B
est: 2.46B (+54.8%)
|
5.11B
est: 4.70B (+8.7%)
|
6.06B
est: 6.14B (-1.3%)
|
7.11B
est: 7.40B (-3.9%)
|
6.83B
est: 7.34B (-7.0%)
|
5.88B
est: 6.81B (-13.8%)
|
7.71B
est: 7.43B (+3.8%)
|
10.24B
est: 9.25B (+10.7%)
|
10.44B
est: 10.39B (+0.6%)
|
8.81B
est: 11.97B (-26.4%)
|
12.57B
est: 12.37B (+1.6%)
|
13.54B
est: 12.76B (+6.1%)
|
15.32B
14.73B – 15.65B
+20.0% YoY
|
17.73B
17.08B – 18.19B
+15.8% YoY
|
19.95B
19.16B – 20.60B
+12.5% YoY
|
22.29B
22.23B – 22.35B
+11.7% YoY
|
| EBIT |
1.03B
est: 1.61B (-36.2%)
|
1.90B
est: 1.60B (+18.9%)
|
3.36B
est: 2.80B (+20.0%)
|
4.60B
est: 4.02B (+14.3%)
|
5.61B
est: 5.25B (+6.9%)
|
6.50B
est: 6.55B (-0.8%)
|
6.23B
est: 6.60B (-5.7%)
|
5.15B
est: 5.78B (-10.9%)
|
6.76B
est: 6.07B (+11.3%)
|
9.08B
est: 6.48B (+40.2%)
|
9.20B
est: 7.28B (+26.4%)
|
7.51B
est: 8.39B (-10.4%)
|
11.21B
est: 10.91B (+2.8%)
|
12.10B
est: 11.03B (+9.7%)
|
13.51B
12.99B – 13.80B
+22.5% YoY
|
15.63B
15.06B – 16.04B
+15.8% YoY
|
17.59B
16.90B – 18.16B
+12.5% YoY
|
19.66B
19.60B – 19.71B
+11.7% YoY
|
| Net Income |
772.60M
est: 1.00B (-22.9%)
|
1.12B
est: 1.12B (-0.2%)
|
2.34B
est: 1.50B (+56.0%)
|
3.10B
est: 2.90B (+7.0%)
|
4.16B
est: 3.65B (+13.7%)
|
5.07B
est: 4.95B (+2.3%)
|
4.69B
est: 5.20B (-9.8%)
|
3.87B
est: 4.53B (-14.5%)
|
4.68B
est: 4.75B (-1.6%)
|
6.54B
est: 5.19B (+25.9%)
|
7.13B
est: 5.83B (+22.2%)
|
5.88B
est: 6.72B (-12.5%)
|
8.16B
est: 8.54B (-4.4%)
|
9.20B
est: 9.30B (-1.0%)
|
10.56B
10.46B – 11.46B
+13.6% YoY
|
12.23B
11.97B – 13.14B
+15.8% YoY
|
14.25B
13.84B – 15.51B
+16.5% YoY
|
15.74B
15.49B – 16.80B
+10.4% YoY
|
| SGA |
1.15B
est: 1.03B (+11.2%)
|
3.32B
est: 3.98B (-16.6%)
|
4.10B
est: 4.63B (-11.5%)
|
2.17B
est: 5.42B (-60.0%)
|
2.77B
est: 5.76B (-51.8%)
|
3.06B
est: 6.65B (-54.0%)
|
3.91B
est: 6.23B (-37.2%)
|
4.50B
est: 7.36B (-38.8%)
|
4.89B
est: 10.34B (-52.7%)
|
5.52B
est: 13.10B (-57.8%)
|
6.57B
est: 14.71B (-55.3%)
|
7.98B
est: 16.95B (-52.9%)
|
9.12B
est: 9.54B (-4.3%)
|
11.05B
est: 22.28B (-50.4%)
|
11.81B
11.36B – 12.06B
-47.0% YoY
|
13.67B
13.17B – 14.02B
+15.8% YoY
|
15.38B
14.77B – 15.88B
+12.5% YoY
|
17.19B
17.14B – 17.23B
+11.7% YoY
|
| EPS |
5.86
est: 8.01 (-26.8%)
|
8.51
est: 13.76 (-38.2%)
|
17.75
est: 26.13 (-32.1%)
|
23.49
est: 22.30 (+5.3%)
|
31.49
est: 29.27 (+7.6%)
|
38.39
est: 39.48 (-2.8%)
|
35.50
est: 37.00 (-4.1%)
|
29.32
est: 28.99 (+1.1%)
|
35.73
est: 33.76 (+5.8%)
|
50.06
est: 49.36 (+1.4%)
|
54.97
est: 58.15 (-5.5%)
|
45.89
est: 50.14 (-8.5%)
|
64.82
est: 67.83 (-4.4%)
|
73.56
est: 75.85 (-3.0%)
|
87.82
83.69 – 91.77
+15.8% YoY
|
100.77
95.80 – 105.17
+14.7% YoY
|
115.23
110.80 – 124.17
+14.3% YoY
|
128.15
123.99 – 134.47
+11.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
2.29B
OE per share TTM
18.25
Owner's Yield
0.59%
Maintenance CapEx ratio
28.46%
Maint CapEx / Avg PPE
46.1%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 24 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Emerging Markets Ex-China ETF VEXC | 0.02% | 39.0K | 0.07% |
| 2 | Vanguard FTSE Asia ex Japan Shares Index ETF VAE.AX | 0.01% | 79.2K | 0.40% |
| 3 | Schwab Emerging Markets Equity ETF SCHE | 0.01% | 1.63M | 0.06% |
| 4 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Accumulating VFEA.L | 0.01% | 690.2K | 0.17% |
| 5 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L | 0.01% | 690.2K | 0.17% |
| 6 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.01% | 154.0K | 0.48% |
| 7 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.01% | 347.3K | 0.26% |
| 8 | Vanguard FTSE Emerging Markets ETF VWO | 0.01% | 17.14M | 0.06% |
| 9 | Vanguard ESG International Stock ETF VSGX | 0.00% | 272.0K | 0.10% |
| 10 | Vanguard All-World ex-US Shares Index ETF VEU.AX | 0.00% | 137.5K | 0.04% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
1.64M
Shares Outstanding
124.94M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Rajesh Mannalal Agrawal | Joint MD & Director | 246M | male |
| Yogesh Mannalal Agrawal | MD & Executive Director | 246M | male |
| Madhusudan Bhagwandas Agrawal | Executive Vice Chairman of the Board | 48M | male |
| H. Satish Agrawal | President of Technical & Operations | — | male |
| Arvind K. Agrawal | Chief Financial Officer | — | male |
| Pourus Vakil | President of Sales & Marketing | — | male |
| Thampy Jacob | Senior Vice President of HR | — | male |
| Pankaj Barbind | Deputy General Manager of Sustainability | — | male |
| Gaurang C. Shah | Senior Vice President of Legal, VP of Corporate Affairs, Company Secretary & Compliance Officer | — | male |
| H. Nandkishore Agrawal | President of International Business | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AJANTPHARM.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
